November 10, 2017 6:11pm

If some of these development platforms are so “robust”, why haven’t they been partnered and less dependent on dilutionary and depreciating financings?

 

Watch your “six”, the reality of about-to-be financings is coming … Capricor (CAPR), Cytori (CYTX) and a maybe Vericel (VCEL) to name a few?

Shareholders are always the sufferers

 

Pre-open indications: 2 hit and 2 miss

 

How right does one have to be? You could and should be reading this review of the day’s share pricing activity?

 

Is the truth so hard to fathom – that’s why my readership has grown exponentially!

 

 

Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s newsletter, “it’s time for a break from the loss-per-share releases as spending and cash positions set expectation as development platform progressions affect a yawn and investors’ debate staying as more than some clinical trials have trouble populating.”

The major U.S. stock indexes closed mostly lower on Friday as the sector pouted to the upside for the second session after three negative closes.

Short-term overbought conditions are still in place, so we think it will take another week of loss-per-share releases to spur the momentum horse to the downside!

  • Momentum seems WEAK to the upside while the downside is likely to initiate a trend that is NOT your friend.

Some of the sector’s “usual suspects” will be listing proposed offerings (VCEL) if they haven’t already (CAPR) this month.

  • Stocks have also been pressured by fears that a bad news bear will drive “perceived” value …

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative with an A/DL of 13/24 and 2 flats ;

·         The mid-day was negative with an A/DL of 15/25 and 3 flats – the opposite of Thursday;

·         The close was positive with an A/DL of 24/20 and 1 flat;

 

Pre-open indications: 2 hit and 2 miss

  • Aduro Biotech (ADRO) closed up +$0.10 – hit;
  • Applied Genetic Technologies (AGTC) closed up +$0.125 – miss;
  • AxoGen (AXGN) closed up +$0.15 – miss;
  • Vericel (VCEL) closed down -$0.15 – hit;

 

 

Some of MY working trend lines or indications:

… The greatest volume to the downside:  XON, NWBO, RENE.L, MDXG and VCEL

… Upside volume was weighted to:  SGMO, JUNO, IMUC, ONVO and BTX

… Biggest $ downside: XON (-$4.07), CLLS (-$0.58), MDXG (-$0.34), VCEL ($0.15) and ADVM (-$0.10)

… Largest $ upside:  JUNO (+$3.16), BLUE (+$1.40), SGMO (+$1.15), BLFS (+$0.76) and STML (+$0.75)

… Flat:  OSIR

 

 

Daily analytics:

U.S. stocks finished the week on a subdued note, as worries over U.S. tax reform and a delay of the promises cut in corporate taxation, weighed on investors' minds.

·         The Dow slipped 0.2% to 23,423, marking its first weekly loss in nine weeks.

·         The S&P 500 dropped 0.1% to finish the week at 2,582 points, also breaking an eight-week winning streak with a slight dip into negative territory on the week.

·         The NASDAQ ended the day marginally higher at 6,751 points, sliding 0.2% on the week.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Friday traded at 11.729, up +7.52% …

  • Thursday traded at 10.50, up +7.36% after Wednesday traded at 9.78, down -1.11% after Tuesday traded at 9.89, up +5.21% after Monday traded at 9.40, up +2.84% after Friday traded at 9.14, down -7.96% and last Thursday traded 9.92, down -2.75% …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Friday was down -0.06%

·         Thursday -0.36%

·         Wednesday +0.16%

·         Tuesday -1.18%

·         Monday +0.14%

·         Last Friday -0.12%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Friday was up +0.37%

·         Thursday -0.56%

·         Wednesday -0.39%

·         Tuesday -0.50%

·         Monday -0.40%

·         Last Friday +1.54%

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

·         Friday’s decliners ranged from -0.28% <KOOL -$0.01> to -25.63% <XON -$4.07> in 18 equities;

·         Thursday’s decliners ranged from -0.12% <CLLS -$0.03> to -5.63% <HSGX -$0.12> in 15 equities;

·         Wednesday’s decliners ranged from -0.34% <CLBS -$0.01> to -9.36% <ONCE -$0.10> in 23 equities;

·         Tuesday’s decliners ranged from -0.60% <NWBO -$0.001> to -8.60% <FCSC -$0.16> in 33 equities;

·         Monday’s decliners ranged from -0.28% <ONCE -$0.23> to -7.36% <BLUE -$11.50> in 30 equities;

·         Last Friday’s decliners ranged from -0.64% <ONVO -$0.01> to -3.21% <MESO -$0.17> in 10 equities;

 

Versus

… Look at the percentage’s (%) and spreads …

·         Friday’s gainers ranged from +0.50% <HSGX +$0.01> to +5.81% <JUNO +$3.16> in 24 equities;

·         Thursday’s gainers ranged from +0.45% <BTX +$0.01> to +9.64% <FCSC +$0.16> in 25 equities;

·         Wednesday’s gainers ranged from +0.30% <NWBO +$0.0005> to +16% <CAPR +$0.32> in 16 equities;

·         Tuesday’s gainers ranged from +0.20% <MESO +$0.01> to +3.15% <MDXG +$0.38> in 8 equities;

·         Monday’s gainers ranged from +0.06% <IMUC +$0.0002> to +20.51% <VTGN -$0.16> in 10 equities;

·         Last Friday’s gainers ranged from +0.23% <CYTX +$0.0009> to +16.44% <OSIR +$0.84> in 29 equities;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.